Harvard Bioscience (NASDAQ:HBIO) Stock Bumped Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Harvard Bioscience (NASDAQ:HBIO – Free Report) to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

A number of other research analysts also recently commented on HBIO. Stonex Financial downgraded shares of Harvard Bioscience from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Benchmark raised their price target on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a report on Wednesday, August 12th. Zacks Research started coverage on Harvard Bioscience in a research note on Tuesday, November 3rd. They set a “hold” rating for the company. StoneX lowered Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a research report on Wednesday, November 11th. Finally, Weiss Ratings upgraded Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.75.

View Our Latest Stock Report on Harvard Bioscience

Harvard Bioscience Stock Performance

Harvard Bioscience stock opened at $8.66 on Friday. Harvard Bioscience has a 52 week low of $4.00 and a 52 week high of $10.20. The company has a current ratio of 1.76, a quick ratio of 0.86 and a debt-to-equity ratio of 7.28. The stock has a fifty day moving average price of $8.43 and a 200 day moving average price of $6.68. The firm has a market capitalization of $39.58 million, a P/E ratio of -3.34 and a beta of 1.47.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. The company had revenue of $22.20 million during the quarter, compared to the consensus estimate of $21.80 million. Equities research analysts anticipate that Harvard Bioscience will post -2.37 earnings per share for the current year.

Hedge Funds Weigh In On Harvard Bioscience

A hedge fund recently bought a new stake in Harvard Bioscience stock. Meros Investment Management LP acquired a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned approximately 4.02% of Harvard Bioscience at the end of the most recent reporting period. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

(Get Free Report)

Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.

See Also

Analyst Recommendations for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.